Table 3.
Summary estimates of relative risks and mean differences for all outcomes of AFA vs controls
| Summary estimates | Relative risk (95% CI) | Patient no. | Events | No. of studies |
|---|---|---|---|---|
| All‐cause mortality (all studies) | 0.52 (0.35, 0.76) | 668 | 98 | 4 |
| Unplanned or heart failure hospitalization (all studies) | 0.58 (0.46, 0.73) | 801 | 205 | 6 |
| Summary estimates | Mean difference (95% CI) | Patient no. | No. of studies | |
| Improvement in LVEF (%) | ||||
| All studies | 6.30 (3.90, 8.71) | 770 | 7 | |
| Newer studies | 5.56 (2.15, 8.97) | 551 | 3 | |
| Older studies | 7.18 (3.39, 10.97) | 219 | 4 | |
| Rate control as control group | 8.33 (4.65, 12.02) | 285 | 5 | |
| Pharmacological rate control as control group | 8.12 (2.63, 13.61) | 204 | 4 | |
| Only PsAF patients | 6.56 (1.62, 11.51) | 381 | 5 | |
| Improvement in MLHFQ score | ||||
| All studies | 9.58 (4.45, 14.71) | 396 | 5 | |
| Newer studies | 5.00 (‐0.30, 10.30) | 177 | 1 | |
| Older studies | 11.88 (6.60, 17.15) | 219 | 4 | |
| Rate control as control group | 11.88 (6.60, 17.15) | 219 | 4 | |
| Pharmacological rate control as control group | 11.73 (3.18, 20.29) | 138 | 3 | |
| Only PsAF patients | 9.07 (2.48, 15.66) | 315 | 4 | |
| Improvement in 6MWD | ||||
| All studies | 31.78 (10.64, 52.93) | 702 | 6 | |
| Newer studies | 30.00 (‐0.40, 60.39) | 537 | 3 | |
| Older studies | 34.76 (2.87, 66.65) | 165 | 3 | |
| Rate control only in control group | 37.72 (13.11, 62.33) | 231 | 4 | |
| Pharmacological rate control as control group | 19.80 (‐12.72, 52.33) | 150 | 3 | |
| Only PsAF patients | 12.87 (2.03, 23.70) | 327 | 4 | |
| Improvement in VO2 max score | ||||
| All studies | 3.17 (1.05, 5.28) | 100 | 2 | |